Table 1.
Drugs in clinical research.
| Drug | R&D Company | Stage of Development |
Reference |
|---|---|---|---|
| Lerociciclib (G1T38) | G1 Therapeutics (North Carolina, NC, USA) | Phase II | [111] |
| Ebvaciclib (PF-06873600) | PFIZER (New York, NY, USA) | Phase I/II | [112] |
| MM-D37K | MetaMax Ltd. (Moscow, Russia) | Phase I/II | [113] |
| BPI-16350 | Beida Pharmaceutical Company (Hangzhou, China) | Phase III | [114] |
| RGT-419B | Shanghai Qilu Ruige Pharmaceutical R&D Co., Ltd. (Shanghai, Chian) | Phase I | [115] |
| FCN-437c | Fuchuang Pharmaceutical Company (Chongqing, China) | Phase I | [116] |
| TY-302 | Zhengzhou Taiji Hongnuo Pharmaceutical Co., Ltd. (Zhengzhou, China) | Phase I | [117] |
| TQB3616 | Zhengda Tianqing Pharmaceutical Co., Ltd. (Lianyungang, China) | Phase III | [118] |
| BEBT-209 | Guangzhou Beibeite Pharmaceutical Co., Ltd. (Guangzhou, China) | Phase II | [119] |
| AMG925(FLX925) | Amgen (FLX BIO) (San Fernando, CA, USA) | Phase I | [120] |
| P-276-00 | Piramal (Mumbai, India) | Phase II | [121] |
| SPH4366 | Shanghai Pharmaceutical Group (Shanghai, China) | Phase II/III | [122] |
| ETH-155008 | Shengke Pharmaceutical (Suzhou, China) | Phase I | [123] |
| Narazaciclib (ON123300) | Onconova Therapeutics Inc. (Newtown, PA, USA) | Phase I/II | [124] |
| CGT-1967 | Suzhou Shengshi Taike Company (Suzhou, China) | Phase I | [125] |
| Auceliciclib | Aucentra Therapeutics (Adelaide, Australia) | Phase I/II | [126] |
| XH-30002 | Shanghai Xunhe Pharmaceutical Technology Co., Ltd. (Shanghai, China) | Phase I | [127] |
| HS-10342 | Hansen Company (Shanghai, China) | Phase I | [128] |
| QHRD110 | Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. (Changzhou, China) | Phase I | [129] |
| NUV-422 | Nuvation Bio. (New York, NY, USA) | Phase II | [130] |